Moleculin Biotech, Inc. (MBRX) 10-Year Financial Performance & Capital Metrics

MBRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutMoleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.Show more

Revenue $0
EBITDA -$27M +10.1%
Net Income -$22M +26.9%
EPS (Diluted) -6.32 +58.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -135.8% -78.5%
ROIC -757.42% -114.6%
Debt/Equity 0.08 +263.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Shares diluted 74.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-37.17%

EPS CAGR

10Y-

5Y-

3Y-

TTM-503.5%

ROCE

10Y Avg-73.2%

5Y Avg-73.21%

3Y Avg-80.2%

Latest-124%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	6.16K	18K	68K	185K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-6.16K	-18K	-68K	-185K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-1.92%	-2.78%	-1.72%	1%	-	-	-	-
Operating Expenses+	738.23K	3.88M	8.65M	15.03M	17.34M	19.74M	22.97M	30.64M	29.63M	26.64M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	477.81K	2.38M	4.09M	5.3M	6.33M	6.79M	8.39M	11.54M	10.02M	8.79M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	260.42K	1.5M	4.54M	9.73M	11.01M	12.76M	14.42M	18.97M	19.49M	17.73M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	6.16K	18K	-40K	0	200K	164K	130K	127K	126K
Operating Income+	-738.23K	-3.88M	-8.65M	-15.03M	-17.52M	-19.74M	-22.97M	-30.64M	-29.63M	-26.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-4.26%	-1.23%	-0.74%	-0.17%	-0.13%	-0.16%	-0.33%	0.03%	0.1%
EBITDA+	1.03M	-3.88M	-8.63M	-14.96M	-17.34M	-19.54M	-22.8M	-30.51M	-29.5M	-26.52M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-4.75%	-1.23%	-0.73%	-0.16%	-0.13%	-0.17%	-0.34%	0.03%	0.1%
D&A (Non-Cash Add-back)	1.77M	6.16K	18K	68K	185K	200K	164K	130K	127K	126K
EBIT	-1.77M	-3.88M	-8.49M	-15.06M	-13.43M	-19.74M	-22.97M	-30.64M	-29.63M	-26.64M
Net Interest Income+	0	0	0	0	13K	13K	306K	240K	1.37M	550K
Interest Income	24.32K	0	0	0	13K	13K	306K	240K	1.37M	550K
Interest Expense	0	43.21K	0	0	0	0	0	0	0	0
Other Income/Expense	-10.13K	-43.36K	-1.15M	3.15M	4.09M	2.39M	7.07M	1.61M	-138K	4.88M
Pretax Income+	-748.36K	-3.93M	-9.8M	-11.88M	-13.43M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	-229K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-4.25%	-1.5%	-0.21%	-0.11%	-0.31%	0.08%	-0.83%	-0.03%	0.27%
Net Income (Continuing)	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-11.83	-35.96	-47.52	-41.26	-29.18	-26.44	-8.87	-15.22	-15.07	-6.32
EPS Growth %	-	-2.04%	-0.32%	0.13%	0.29%	0.09%	0.66%	-0.72%	0.01%	0.58%
EPS (Basic)	-11.88	-35.96	-47.52	-41.26	-29.18	-26.44	-8.87	-15.22	-15.07	-6.32
Diluted Shares Outstanding	63.24K	109.19K	206.32K	287.82K	452.46K	656.38K	1.79M	1.91M	1.98M	3.44M
Basic Shares Outstanding	63K	109.19K	206.32K	287.82K	452.46K	656.38K	1.79M	1.91M	1.98M	3.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.09K	5.22M	8.3M	7.97M	13.48M	17.2M	72.5M	45.6M	26.27M	5.19M
Cash & Short-Term Investments	28.09K	5.01M	7.71M	7.13M	10.73M	15.17M	70.9M	43.15M	23.55M	4.28M
Cash Only	28.09K	5.01M	7.71M	7.13M	10.73M	15.17M	70.9M	43.15M	23.55M	4.28M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	56K	11K	1K	45K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	784K	2.39M	1.45M	486K	823K	644K	351K
Total Non-Current Assets+	3K	11.17M	11.18M	11.61M	11.75M	11.96M	11.59M	11.83M	11.94M	11.73M
Property, Plant & Equipment	0	23.13K	33K	463K	603K	685K	445K	678K	796K	583K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M
Long-Term Investments	3K	0	0	0	0	129K	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	28.09K	16.39M	19.48M	19.59M	25.23M	29.16M	84.09M	57.42M	38.22M	16.93M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	582.57%	0.19%	0.01%	0.29%	0.16%	1.88%	-0.32%	-0.33%	-0.56%
Total Current Liabilities+	772.79K	1.35M	2.21M	3.88M	3.57M	2.92M	3.62M	4.82M	6.82M	5.36M
Accounts Payable	0	399K	810K	1.25M	2.15M	1.13M	1.36M	2.1M	2.5M	2.03M
Days Payables Outstanding	-	23.63K	16.43K	6.69K	4.25K	-	-	-	-	-
Short-Term Debt	450K	296K	0	0	103K	118K	96K	0	0	0
Deferred Revenue (Current)	-235.29K	-399K	0	0	0	0	0	0	0	0
Other Current Liabilities	87.5K	67	1.16M	2.29M	878K	1.25M	1.56M	0	0	0
Current Ratio	0.04x	3.88x	3.75x	2.06x	3.78x	5.89x	20.02x	9.46x	3.86x	0.97x
Quick Ratio	0.04x	3.88x	3.75x	2.06x	3.78x	5.89x	20.02x	9.46x	3.86x	0.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	450K	87.5K	150K	1.44M	6.09M	8.35M	1.48M	412K	5.33M	5.59M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	276K	159K	63K	335K	474K	358K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	87.5K	150K	1.44M	5.82M	8.19M	1.41M	77K	4.86M	5.23M
Total Liabilities	772.79K	1.43M	2.37M	5.31M	9.66M	11.27M	5.1M	5.23M	12.14M	10.95M
Total Debt+	450K	296.41K	0	0	379K	277K	159K	451K	574K	478K
Net Debt	421.91K	-4.71M	-7.71M	-7.13M	-10.36M	-14.9M	-70.74M	-42.69M	-22.98M	-3.8M
Debt / Equity	-	0.02x	-	-	0.02x	0.02x	0.00x	0.01x	0.02x	0.08x
Debt / EBITDA	0.44x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	0.41x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-89.86x	-	-	-	-	-	-	-	-
Total Equity+	-744.7K	14.96M	17.12M	14.27M	15.57M	17.89M	78.99M	52.19M	26.07M	5.98M
Equity Growth %	-	21.09%	0.14%	-0.17%	0.09%	0.15%	3.42%	-0.34%	-0.5%	-0.77%
Book Value per Share	-11.78	137.01	82.97	49.59	34.41	27.25	44.09	27.37	13.20	1.74
Total Shareholders' Equity	-744.7K	14.96M	17.12M	14.27M	15.57M	17.89M	78.99M	52.19M	26.07M	5.98M
Common Stock	6.66K	12.16K	21K	29K	46K	69K	29K	29K	33K	3K
Retained Earnings	-748.36K	-4.67M	-14.48M	-26.36M	-39.56M	-56.92M	-72.81M	-101.83M	-131.6M	-153.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3K	0	0	35K	31K	65K	41K	12K	-9K	-41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-423.51K	-3.76M	-7.32M	-12.2M	-17.2M	-17.77M	-18.95M	-27.64M	-24.1M	-23.86M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-7.89%	-0.95%	-0.67%	-0.41%	-0.03%	-0.07%	-0.46%	0.13%	0.01%
Net Income	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Depreciation & Amortization	0	6.16K	18K	68K	199K	200K	164K	130K	127K	126K
Stock-Based Compensation	0	411.47K	707K	1.14M	1.54M	1.68M	2.37M	2.27M	1.98M	1.73M
Deferred Taxes	0	0	-1.39M	0	0	-2.34M	-6.73M	0	0	0
Other Non-Cash Items	2.06K	423.8K	2.6M	-3.15M	-3.59M	85K	96K	-1.24M	1.94M	-4.18M
Working Capital Changes	322.79K	-256.18K	542K	1.61M	-2.14M	-41K	1.04M	224K	1.62M	231K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	-41.13M	411K	436K	907K	-1.02M	235K	731K	403K	-468K
Cash from Investing+	0	-121.11K	-28K	-417K	-51K	-374K	-19K	-67K	-124K	-13K
Capital Expenditures	0	-21.47K	-28K	-417K	-52K	-376K	-19K	-67K	-124K	-13K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1K	0	0	0	0	0
Cash from Financing+	451.6K	8.87M	10.06M	12.04M	20.85M	22.55M	74.72M	-23K	4.65M	4.63M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-61	3.99M	20K	1.56M	-12K	40K	0	485K	-25K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-423.51K	-3.79M	-7.35M	-12.62M	-17.25M	-18.15M	-18.97M	-27.71M	-24.23M	-23.88M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-7.94%	-0.94%	-0.72%	-0.37%	-0.05%	-0.05%	-0.46%	0.13%	0.01%
FCF per Share	-6.70	-34.68	-35.63	-43.85	-38.12	-27.65	-10.59	-14.53	-12.26	-6.93
FCF Conversion (FCF/Net Income)	0.57x	0.96x	0.75x	1.03x	1.30x	1.02x	1.19x	0.95x	0.81x	1.10x
Interest Paid	0	0	0	5K	1K	0	0	0	0	0
Taxes Paid	0	0	0	21K	19K	24K	15K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-55.24%	-61.13%	-75.67%	-88.5%	-103.74%	-32.81%	-44.25%	-76.07%	-135.8%
Return on Invested Capital (ROIC)	-	-58.68%	-66.04%	-136.24%	-212.79%	-360.78%	-306.46%	-258.99%	-352.92%	-757.42%
Debt / Equity	-	0.02x	-	-	0.02x	0.02x	0.00x	0.01x	0.02x	0.08x
Interest Coverage	-	-89.86x	-	-	-	-	-	-	-	-
FCF Conversion	0.57x	0.96x	0.75x	1.03x	1.30x	1.02x	1.19x	0.95x	0.81x	1.10x

Frequently Asked Questions

Growth & Financials

Moleculin Biotech, Inc. (MBRX) grew revenue by 0.0% over the past year. Growth has been modest.

Moleculin Biotech, Inc. (MBRX) reported a net loss of $41.4M for fiscal year 2024.

Dividend & Returns

Moleculin Biotech, Inc. (MBRX) has a return on equity (ROE) of -135.8%. Negative ROE indicates the company is unprofitable.

Moleculin Biotech, Inc. (MBRX) had negative free cash flow of $22.5M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Moleculin Biotech, Inc. (MBRX) 10-Year Financial Performance & Capital Metrics

MBRX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0
EBITDA -$27M +10.1%
Net Income -$22M +26.9%
EPS (Diluted) -6.32 +58.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -135.8% -78.5%
ROIC -757.42% -114.6%
Debt/Equity 0.08 +263.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 98 (top 2%)

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Shares diluted 74.3% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-37.17%

EPS CAGR

10Y-

5Y-

3Y-

TTM-503.5%

ROCE

10Y Avg-73.2%

5Y Avg-73.21%

3Y Avg-80.2%

Latest-124%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	6.16K	18K	68K	185K	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	-6.16K	-18K	-68K	-185K	0	0	0	0	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-1.92%	-2.78%	-1.72%	1%	-	-	-	-
Operating Expenses+	738.23K	3.88M	8.65M	15.03M	17.34M	19.74M	22.97M	30.64M	29.63M	26.64M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	477.81K	2.38M	4.09M	5.3M	6.33M	6.79M	8.39M	11.54M	10.02M	8.79M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	260.42K	1.5M	4.54M	9.73M	11.01M	12.76M	14.42M	18.97M	19.49M	17.73M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	6.16K	18K	-40K	0	200K	164K	130K	127K	126K
Operating Income+	-738.23K	-3.88M	-8.65M	-15.03M	-17.52M	-19.74M	-22.97M	-30.64M	-29.63M	-26.64M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-4.26%	-1.23%	-0.74%	-0.17%	-0.13%	-0.16%	-0.33%	0.03%	0.1%
EBITDA+	1.03M	-3.88M	-8.63M	-14.96M	-17.34M	-19.54M	-22.8M	-30.51M	-29.5M	-26.52M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-4.75%	-1.23%	-0.73%	-0.16%	-0.13%	-0.17%	-0.34%	0.03%	0.1%
D&A (Non-Cash Add-back)	1.77M	6.16K	18K	68K	185K	200K	164K	130K	127K	126K
EBIT	-1.77M	-3.88M	-8.49M	-15.06M	-13.43M	-19.74M	-22.97M	-30.64M	-29.63M	-26.64M
Net Interest Income+	0	0	0	0	13K	13K	306K	240K	1.37M	550K
Interest Income	24.32K	0	0	0	13K	13K	306K	240K	1.37M	550K
Interest Expense	0	43.21K	0	0	0	0	0	0	0	0
Other Income/Expense	-10.13K	-43.36K	-1.15M	3.15M	4.09M	2.39M	7.07M	1.61M	-138K	4.88M
Pretax Income+	-748.36K	-3.93M	-9.8M	-11.88M	-13.43M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	-229K	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	0.98%	1%	1%	1%	1%	1%
Net Income+	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-4.25%	-1.5%	-0.21%	-0.11%	-0.31%	0.08%	-0.83%	-0.03%	0.27%
Net Income (Continuing)	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-11.83	-35.96	-47.52	-41.26	-29.18	-26.44	-8.87	-15.22	-15.07	-6.32
EPS Growth %	-	-2.04%	-0.32%	0.13%	0.29%	0.09%	0.66%	-0.72%	0.01%	0.58%
EPS (Basic)	-11.88	-35.96	-47.52	-41.26	-29.18	-26.44	-8.87	-15.22	-15.07	-6.32
Diluted Shares Outstanding	63.24K	109.19K	206.32K	287.82K	452.46K	656.38K	1.79M	1.91M	1.98M	3.44M
Basic Shares Outstanding	63K	109.19K	206.32K	287.82K	452.46K	656.38K	1.79M	1.91M	1.98M	3.44M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	28.09K	5.22M	8.3M	7.97M	13.48M	17.2M	72.5M	45.6M	26.27M	5.19M
Cash & Short-Term Investments	28.09K	5.01M	7.71M	7.13M	10.73M	15.17M	70.9M	43.15M	23.55M	4.28M
Cash Only	28.09K	5.01M	7.71M	7.13M	10.73M	15.17M	70.9M	43.15M	23.55M	4.28M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	56K	11K	1K	45K	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	784K	2.39M	1.45M	486K	823K	644K	351K
Total Non-Current Assets+	3K	11.17M	11.18M	11.61M	11.75M	11.96M	11.59M	11.83M	11.94M	11.73M
Property, Plant & Equipment	0	23.13K	33K	463K	603K	685K	445K	678K	796K	583K
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M	11.15M
Long-Term Investments	3K	0	0	0	0	129K	0	0	0	0
Other Non-Current Assets	0	0	0	0	0	0	0	0	0	0
Total Assets+	28.09K	16.39M	19.48M	19.59M	25.23M	29.16M	84.09M	57.42M	38.22M	16.93M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	582.57%	0.19%	0.01%	0.29%	0.16%	1.88%	-0.32%	-0.33%	-0.56%
Total Current Liabilities+	772.79K	1.35M	2.21M	3.88M	3.57M	2.92M	3.62M	4.82M	6.82M	5.36M
Accounts Payable	0	399K	810K	1.25M	2.15M	1.13M	1.36M	2.1M	2.5M	2.03M
Days Payables Outstanding	-	23.63K	16.43K	6.69K	4.25K	-	-	-	-	-
Short-Term Debt	450K	296K	0	0	103K	118K	96K	0	0	0
Deferred Revenue (Current)	-235.29K	-399K	0	0	0	0	0	0	0	0
Other Current Liabilities	87.5K	67	1.16M	2.29M	878K	1.25M	1.56M	0	0	0
Current Ratio	0.04x	3.88x	3.75x	2.06x	3.78x	5.89x	20.02x	9.46x	3.86x	0.97x
Quick Ratio	0.04x	3.88x	3.75x	2.06x	3.78x	5.89x	20.02x	9.46x	3.86x	0.97x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	450K	87.5K	150K	1.44M	6.09M	8.35M	1.48M	412K	5.33M	5.59M
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	276K	159K	63K	335K	474K	358K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	87.5K	150K	1.44M	5.82M	8.19M	1.41M	77K	4.86M	5.23M
Total Liabilities	772.79K	1.43M	2.37M	5.31M	9.66M	11.27M	5.1M	5.23M	12.14M	10.95M
Total Debt+	450K	296.41K	0	0	379K	277K	159K	451K	574K	478K
Net Debt	421.91K	-4.71M	-7.71M	-7.13M	-10.36M	-14.9M	-70.74M	-42.69M	-22.98M	-3.8M
Debt / Equity	-	0.02x	-	-	0.02x	0.02x	0.00x	0.01x	0.02x	0.08x
Debt / EBITDA	0.44x	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	0.41x	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-89.86x	-	-	-	-	-	-	-	-
Total Equity+	-744.7K	14.96M	17.12M	14.27M	15.57M	17.89M	78.99M	52.19M	26.07M	5.98M
Equity Growth %	-	21.09%	0.14%	-0.17%	0.09%	0.15%	3.42%	-0.34%	-0.5%	-0.77%
Book Value per Share	-11.78	137.01	82.97	49.59	34.41	27.25	44.09	27.37	13.20	1.74
Total Shareholders' Equity	-744.7K	14.96M	17.12M	14.27M	15.57M	17.89M	78.99M	52.19M	26.07M	5.98M
Common Stock	6.66K	12.16K	21K	29K	46K	69K	29K	29K	33K	3K
Retained Earnings	-748.36K	-4.67M	-14.48M	-26.36M	-39.56M	-56.92M	-72.81M	-101.83M	-131.6M	-153.37M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-3K	0	0	35K	31K	65K	41K	12K	-9K	-41K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-423.51K	-3.76M	-7.32M	-12.2M	-17.2M	-17.77M	-18.95M	-27.64M	-24.1M	-23.86M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-7.89%	-0.95%	-0.67%	-0.41%	-0.03%	-0.07%	-0.46%	0.13%	0.01%
Net Income	-748.36K	-3.93M	-9.8M	-11.88M	-13.21M	-17.36M	-15.89M	-29.02M	-29.77M	-21.76M
Depreciation & Amortization	0	6.16K	18K	68K	199K	200K	164K	130K	127K	126K
Stock-Based Compensation	0	411.47K	707K	1.14M	1.54M	1.68M	2.37M	2.27M	1.98M	1.73M
Deferred Taxes	0	0	-1.39M	0	0	-2.34M	-6.73M	0	0	0
Other Non-Cash Items	2.06K	423.8K	2.6M	-3.15M	-3.59M	85K	96K	-1.24M	1.94M	-4.18M
Working Capital Changes	322.79K	-256.18K	542K	1.61M	-2.14M	-41K	1.04M	224K	1.62M	231K
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	0	-41.13M	411K	436K	907K	-1.02M	235K	731K	403K	-468K
Cash from Investing+	0	-121.11K	-28K	-417K	-51K	-374K	-19K	-67K	-124K	-13K
Capital Expenditures	0	-21.47K	-28K	-417K	-52K	-376K	-19K	-67K	-124K	-13K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	1K	0	0	0	0	0
Cash from Financing+	451.6K	8.87M	10.06M	12.04M	20.85M	22.55M	74.72M	-23K	4.65M	4.63M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	-61	3.99M	20K	1.56M	-12K	40K	0	485K	-25K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-423.51K	-3.79M	-7.35M	-12.62M	-17.25M	-18.15M	-18.97M	-27.71M	-24.23M	-23.88M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-7.94%	-0.94%	-0.72%	-0.37%	-0.05%	-0.05%	-0.46%	0.13%	0.01%
FCF per Share	-6.70	-34.68	-35.63	-43.85	-38.12	-27.65	-10.59	-14.53	-12.26	-6.93
FCF Conversion (FCF/Net Income)	0.57x	0.96x	0.75x	1.03x	1.30x	1.02x	1.19x	0.95x	0.81x	1.10x
Interest Paid	0	0	0	5K	1K	0	0	0	0	0
Taxes Paid	0	0	0	21K	19K	24K	15K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-55.24%	-61.13%	-75.67%	-88.5%	-103.74%	-32.81%	-44.25%	-76.07%	-135.8%
Return on Invested Capital (ROIC)	-	-58.68%	-66.04%	-136.24%	-212.79%	-360.78%	-306.46%	-258.99%	-352.92%	-757.42%
Debt / Equity	-	0.02x	-	-	0.02x	0.02x	0.00x	0.01x	0.02x	0.08x
Interest Coverage	-	-89.86x	-	-	-	-	-	-	-	-
FCF Conversion	0.57x	0.96x	0.75x	1.03x	1.30x	1.02x	1.19x	0.95x	0.81x	1.10x

Frequently Asked Questions

Growth & Financials

Moleculin Biotech, Inc. (MBRX) grew revenue by 0.0% over the past year. Growth has been modest.

Moleculin Biotech, Inc. (MBRX) reported a net loss of $41.4M for fiscal year 2024.

Dividend & Returns

Moleculin Biotech, Inc. (MBRX) has a return on equity (ROE) of -135.8%. Negative ROE indicates the company is unprofitable.

Moleculin Biotech, Inc. (MBRX) had negative free cash flow of $22.5M in fiscal year 2024, likely due to heavy capital investments.